SCHEMBL2402507

SCHEMBL2402507

O=C(O)C1=NOC2(CCN(C(=O)C=Cc3ccccc3)CC2)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.53
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
POLB P06746 2/20 0.50
GAA P10253 2/20 0.47
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
ME2 P23368 1/20 0.45
ME1 P48163 1/20 0.45
ME3 Q16798 1/20 0.45
AR P10275 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NPC1 O15118 4/20 0.44
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
GPR183 P32249 3/20 0.42
TACR3 P29371 1/20 0.41
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GRIN1 Q05586 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6410324 1.00 RAB9A (0.53) RAB9AKMT2AMEN1POLBGAA
SCHEMBL6411469 0.83 RAB9A (0.50) RAB9AKMT2AMEN1POLBGAA
SCHEMBL2401534 0.80 HPGD (0.42) RAB9AKMT2AMEN1POLBGAA
SCHEMBL15309119 0.78 RAB9A (0.56) RAB9AKMT2AMEN1POLBGAA
SCHEMBL5116128 0.78 RAB9A (0.54) RAB9AKMT2AMEN1POLBGAA
SCHEMBL5128958 0.76 LMNA (0.45) RAB9AKMT2AMEN1POLBLMNA
SCHEMBL5015830 0.76 LMNA (0.45) RAB9AKMT2AMEN1POLBLMNA
SCHEMBL14033840 0.76 RAB9A (0.54) RAB9AKMT2AMEN1POLBLMNA
SCHEMBL5124973 0.76 RAB9A (0.54) RAB9AKMT2AMEN1POLBLMNA
SCHEMBL5129892 0.76 GPR183 (0.46) RAB9AKMT2AMEN1POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401841-B1 SUBSTITUTED 1-OXA-2,8-DIAZA-SPIRO 4,5]DEC-2-ENE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2005-08-24 EP claimed
US-20040192916-A1 Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives and related treatment methods GRUENENTHAL GMBH (DE) 2004-09-30 US claimed
US-8557796-B2 Substituted 1-oxa-2,8-diaza-spiro [4,5] dec-2-ene derivatives and related treatment methods GRUENENTHAL GMBH (DE) 2013-10-15 US disclosed
US-8048890-B2 Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents GRUENENTHAL GMBH (DE) 2011-11-01 US disclosed
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods GRUENENTHAL GMBH (DE) 2011-09-15 US disclosed
US-20040192916-A1 Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives and related treatment methods GRUENENTHAL GMBH (DE) 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192916-A1 Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives and related treatment methods SULT1E1, CYP4B1, CYP3A4 RAB9A 2779/4885KMT2A 3833/4885MEN1 2802/4885
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods SULT1E1, DECR1, CYP8B1 RAB9A 2221/4885KMT2A 3636/4885MEN1 2995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.